title: Surface antibody and cytokine response to recombinant Chinese hamster ovary cell (CHO) hepatitis B vaccine.
abstract: OBJECTIVE
  To compare the immune responses of the 10 μg and 20 μg doses of CHO hepatitis B vaccine on adults.
  
  
  METHODS
  Adults aged 18-45 years who gave a history of never having received hepatitis B vaccine and lacked serologic evidence of infection to hepatitis B virus (HBV) infection or previous vaccination were enrolled into the study. A total of 642 eligible participants were randomized to receive 3 doses of either the 10 μg or the 20 μg formulation of CHO hepatitis B vaccine in a 0-1-6 month schedule. Each study subject had a serologic specimen collected one month following the third vaccine dose that was tested for markers of HBV infection and anti-HBs by Abbott I2000. Persons who tested negative for anti-HBs negative persons were tested for HBV DNA. Logistic regression was used to identify factors associated with antibody response. Among the participants, 153 subjects had their lymphocytes cultivated and tested for cytokine production. Enzyme-linked immunospot (ELISPOT) was used to test spot numbers of IL-4, IFN-γ which produced by lymphocyte.
  
  
  RESULTS
  The anti-HBs seroconversion rate was 88.8% (95% CI: 85.4-92.2%) and 95.3% (95% CI: 93.0-97.6%), respectively in 10 μg and 20 μg group. Geometric mean titers (GMT) were 173.42 mIU/ml and 585.51 mIU/ml, respectively in 10 μg and 20 μg groups. Multivariate analysis demonstrated that diabetes, spouse is hepatitis B virus infector, older age and receipt of the 10 μg dose were all negatively associated with antibody response (P<.05). Cellular immunity results showed: IL-4 immunity spot numbers in 20 μg group was higher than 10 μg group. With anti-HBs increased, the IL-4 immunity spot numbers increased significantly which had significant positive correlation (Spearman coefficient=0.538, P<0.0001). IFN-γ spot numbers had no statistical significant between the two groups.
  
  
  CONCLUSIONS
  The humoral immunity and cytokines response among the group that received the 20 μg CHO hepatitis B vaccine dose was superior compared to the group that received the 10 μg dose. The 20 μg dose of CHO hepatitis B vaccine should be prioritized for adult vaccination programs in China.
authors: Beijing Center for Disease Control and Prevention, Beijing 100013, China.
authors: Wei
authors: W
authors: Zhang
authors: Lili
authors: L
authors: Han
authors: Changying
authors: C
authors: Lin
authors: Huai
authors: H
authors: Wang
authors: Xinghuo
authors: X
authors: Pang
authors: Liqiu
authors: L
authors: Li
authors: Pei
authors: P
authors: Gao
authors: Hui
authors: H
authors: Lin
authors: Xiaohong
authors: X
authors: Gong
authors: Yaqing
authors: Y
authors: Tang
authors: Jianxin
authors: J
authors: Ma
authors: Haiyan
authors: H
authors: Zhang
authors: Chen
authors: C
authors: Wang
authors: Peng
authors: P
authors: Yang
authors: Hui
authors: H
authors: Li
authors: Meiping
authors: M
authors: Sun
authors: Xiong
authors: X
authors: He
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000818:Animals; D000917:Antibody Formation / Q000276:immunology; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D016207:Cytokines / Q000096:biosynthesis; D004279:DNA, Viral / Q000097:blood; D003920:Diabetes Mellitus; D058501:Enzyme-Linked Immunospot Assay; D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000096:biosynthesis / Q000097:blood / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D006801:Humans; D007117:Immunization, Secondary; D008297:Male; D008875:Middle Aged; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
chemical_list: D016207:Cytokines; D004279:DNA, Viral; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic